CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 30,118	$ 40,992
Prepaid expenses and other current assets	1,600	2,531
Research and development incentives receivables	1,683	1,497
Total current assets	33,401	45,020
Property and equipment, net	54	137
Operating lease right-of-use assets, net	1,003	244
Intangible assets, net	256	516
Total assets	34,714	45,917
Current liabilities:
Accounts payable	1,121	1,333
Accrued expenses	2,455	2,026
Operating lease liabilities - current	1,030	202
Other current liabilities	1,071	741
Total current liabilities	5,677	4,302
Warrant liabilities - non-current	15	38
Other non-current liabilities	370	661
Total liabilities	6,062	5,001
Commitments and contingencies (Note 15)
Shareholders' Equity
Ordinary shares, par value 0.003 per share; 798,093,044 shares issued at June 30, 2026 (December 31, 2025: 795,658,504)	3,145	3,135
Additional paid-in capital	552,335	549,622
Accumulated deficit	(514,543)	(501,018)
Accumulated other comprehensive loss	(12,285)	(10,823)
Total shareholders' equity	28,652	40,916
Total liabilities and shareholders' equity	$ 34,714	$ 45,917

Current portion of research and development incentives receivables.

No definition available.

Name:	mreo_ResearchAndDevelopmentIncentivesReceivablesCurrent
Namespace Prefix:	mreo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).